Empagliflozin + Matching placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Kidney Disease
Conditions
Chronic Kidney Disease
Trial Timeline
Jan 31, 2019 → Jul 2, 2024
NCT ID
NCT03594110About Empagliflozin + Matching placebo
Empagliflozin + Matching placebo is a phase 3 stage product being developed by Eli Lilly for Chronic Kidney Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03594110. Target conditions include Chronic Kidney Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03594110 | Phase 3 | Completed |
Competing Products
20 competing products in Chronic Kidney Disease